Table 3.

Baseline characteristics of studies in resistant P. aeruginosa

Author	Year	Design	Country	Case/Exposure	Control/Comparator	Total N	Age cases (Yr)	Age control (Yr)	Male cases (%)	Male controls (%)
Akhabue [41]	2011	CC, unmatched	USA	Cefepime-resistant P.aeruginosa	Cefepime-susceptible P.aeruginosa	2529	Median:61 (total)	Median:61 (total)	62	56.4
Fortaleza (b) [45]	2006	CC, matched	Brazil	Ceftazidime-resistant P.aeruginosa	Control	165	median 38	median 44.5	72.7	62.7
Gasink [48]	2006	CC, unmatched	USA	Fluoroquinolone-resistant P.aeruginosa	Fluoroquinolone-susceptible P.aeruginosa	847	56	62	NR	NR
Harris [49]	2002	CC, unmatched	USA	Piperacillin-tazobactam-resistant P. aeruginosa	Patients without Piperacillin-tazobactam-resistant P. aeruginosa	1315	53.4	49.7	42.5	39.4
Hsu [52]	2005	CC, unmatched	USA	Fluoroquinolone-resistant P.aeruginosa	Fluoroquinolone-susceptible P.aeruginosa	177	73.8	68	43	49
Khayr [53]	2000	CC, unmatched	USA	Ciprofloxacin-resistant P.aeruginosa	Ciprofloxacin-susceptible P.aeruginosa	94	Age > 65: 79%	Age > 65: 79%	100	100
Trouillet [63]	2002	CC, unmatched	France	Piperacillin-resistant P. aeruginosa	Piperacillin-susceptible P. aeruginosa	135	64.6	65.5	67.6	64.4

CC case-control, NR not reported, YR year